Pinsent Masons advises Numis on £75 million Cambridge Innovation Capital fundraising

22 Aug 2016 | 03:21 pm |

International law firm Pinsent Masons has advised Numis on a £75 million fundraising for University of Cambridge investor, Cambridge Innovation Capital (CIC).

The funds will be used to provide investment to CIC's portfolio of technology businesses developed by the University of Cambridge and the wider Cambridge cluster, Europe's largest technology hub.

CIC launched in 2013 to provide growth capital to local tech businesses providing long term capital to support the sustained growth of investee companies.

A team at Pinsent Masons was led by corporate partner Russell Booker, assisted by corporate associate James Kaye.

Commenting on the deal Booker said: "This fundraising will be transformational for CIC and for the businesses it invests in. There has been a significant increase of new tech-based investment opportunities signalling a healthy pipeline of opportunities for CIC. We are delighted to have played a significant role in ensuring this valuable work continues."

Latest press releases

Show me all press releases

Pinsent Masons advises Bodymed AG on the sale to Nestlé Health Science

The multinational law firm Pinsent Masons advises the holding company of the founder Dr Hardy Walle on the sale of all shares of Bodymed AG to Nestlé Health Science.

Pinsent Masons secures 11th place in Financial Times Diversity Leaders 2021 Report

Multinational law firm Pinsent Masons has been named as a top 20 Diversity Leader by the Financial Times, ranked 11th in its Diversity Leaders 2021 report.

Pinsent Masons advises shareholders of Goodtill on its sale to SumUp

Multinational law firm Pinsent Masons has advised the shareholders of Goodtill on its sale to SumUp

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Bodymed AG on the sale to Nestlé Health Science

The multinational law firm Pinsent Masons advises the holding company of the founder Dr Hardy Walle on the sale of all shares of Bodymed AG to Nestlé Health Science.

Pinsent Masons advises shareholders of Goodtill on its sale to SumUp

Multinational law firm Pinsent Masons has advised the shareholders of Goodtill on its sale to SumUp

Pinsent Masons advises 4D Pharma PLC on innovative move to NASDAQ

Multinational law firm Pinsent Masons has advised AIM listed biotech company 4D Pharma plc (4D) on its acquisition of Longevity Acquisition Corporation, a special-purpose acquisition company (SPAC) listed on NASDAQ. Upon completion of the transaction 4D will apply for its American Depositary Shares to be admitted to trading on NASDAQ.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts